Developing Protein-Based Nanoparticles as Versatile Delivery Systems for Cancer Therapy and Imaging
-
- Febrina Sandra
- Department of Molecular Sciences, Macquarie University, Sydney 2109, Australia
-
- Nisar Ul Khaliq
- College of Pharmacy, Korea University, 2511 Sejong-ro, Sejong 30019, Korea
-
- Anwar Sunna
- Department of Molecular Sciences, Macquarie University, Sydney 2109, Australia
-
- Andrew Care
- Department of Molecular Sciences, Macquarie University, Sydney 2109, Australia
書誌事項
- 公開日
- 2019-09-16
- 権利情報
-
- https://creativecommons.org/licenses/by/4.0/
- DOI
-
- 10.3390/nano9091329
- 公開者
- MDPI AG
説明
<jats:p>In recent years, it has become apparent that cancer nanomedicine’s reliance on synthetic nanoparticles as drug delivery systems has resulted in limited clinical outcomes. This is mostly due to a poor understanding of their “bio–nano” interactions. Protein-based nanoparticles (PNPs) are rapidly emerging as versatile vehicles for the delivery of therapeutic and diagnostic agents, offering a potential alternative to synthetic nanoparticles. PNPs are abundant in nature, genetically and chemically modifiable, monodisperse, biocompatible, and biodegradable. To harness their full clinical potential, it is important for PNPs to be accurately designed and engineered. In this review, we outline the recent advancements and applications of PNPs in cancer nanomedicine. We also discuss the future directions for PNP research and what challenges must be overcome to ensure their translation into the clinic.</jats:p>
収録刊行物
-
- Nanomaterials
-
Nanomaterials 9 (9), 1329-, 2019-09-16
MDPI AG
